Gastric Cancer
Conditions
Keywords
cisplatin, capecitabine, gastric, irinotecan, metastatic, chemotherapy
Brief summary
The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of progression-free survival, 1-year survival, Quality of Life and safety
Detailed description
capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO 2006)
Interventions
DRUGCisplatin, Irinotecan, Capecitabine
Sponsors
Johannes Gutenberg University Mainz
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* gastric or gastric-oesophagal junction adenocarcinoma * unidimensional measurable disease * Karnofsky index \>/=60%
Exclusion criteria
* prior chemo- or radiotherapy * colorectal diseases * brain metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| safety | — |
| progression free survival | — |
| 1 year survival | — |
| Quality of Life | — |
| Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients | — |
Countries
Germany
Outcome results
None listed